Company profile: Avigen
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D focused on treatments for neurological and other disorders. Develops the AV411 portfolio, including a phase II-stage lead drug compound and proprietary analogs, representing novel, non-opioid drugs for the treatment of pain.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avigen
Hyperion Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on treating urea cycle disorders and other rare diseases for orphan or underserved patient populations; based in South San Francisco, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hyperion Therapeutics company profile →
Quellis Bio
HQ: United States
Website
- Description: Provider of next-generation antibody therapies aimed at improving outcomes for patients with serious rare diseases, focusing on discovering best-in-class new molecules to address underserved treatment needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quellis Bio company profile →
Oxyrane
HQ: United Kingdom
Website
- Description: Provider of novel and biosuperior enzyme replacement therapies for lysosomal storage diseases. Pipeline includes OxyGCase for neuronopathic Gaucher disease and OXY2810 for Pompe disease. Offers the OxyCAT glycoengineered yeast-based platform to produce ERTs with enhanced cellular uptake and pharmacodynamics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxyrane company profile →
Imara
HQ: United States
Website
- Description: Provider of novel therapeutics for people living with sickle cell disease and hemoglobinopathies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imara company profile →
Primrose Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on creating treatments for polycystic kidney disease (PKD), a life-threatening genetic disorder affecting 600,000 Americans and 12.5 million people worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primrose Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avigen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avigen
2.2 - Growth funds investing in similar companies to Avigen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avigen
4.2 - Public trading comparable groups for Avigen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →